Myriad Genetics logo

Myriad GeneticsNASDAQ: MYGN

Profile

Sector:

Healthcare

Country:

United States

IPO:

06 October 1995

Next earnings report:

07 November 2024

Last dividends:

N/A

Next dividends:

N/A
$1.62 B
-38%vs. 3y high
78%vs. sector
-vs. 3y high
-vs. sector
-38%vs. 3y high
60%vs. sector
-57%vs. 3y high
37%vs. sector

Price

after hours | 53 min ago
$17.85-$0.12(-0.67%)

Dividend

No data over the past 3 years
$211.50 M$210.73 M
$211.50 M-$36.70 M

Analysts recommendations

Institutional Ownership

MYGN Latest News

Myriad Genetics, Inc. Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - MYGN
accesswire.com04 November 2024 Sentiment: -

NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. On October 31, 2024, it was revealed that UnitedHealth Group ("UnitedHealth") would no longer cover GeneSight, Myriad's genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025.

Myriad Genetics Comments on UnitedHealthcare's Updated Medical Policy for Pharmacogenetic Testing
globenewswire.com04 November 2024 Sentiment: NEGATIVE

SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, under its commercial and individual exchange benefit plans, effective January 1st, 2025. After initial review of the updated policy, the company strongly disagrees with UnitedHealthcare's inclusion of GeneSight in its decision to change its coverage policy of multi-gene panels based on its rationale that there is insufficient evidence of efficacy to support coverage of GeneSight.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myriad Genetics, Inc. - MYGN
accesswire.com01 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Myriad Genetics, Inc. ("Myriad" or the "Company") (NASDAQ:MYGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
globenewswire.com30 October 2024 Sentiment: POSITIVE

SALT LAKE CITY, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Thursday, November 7, 2024 at 4:30 pm ET. The company's quarterly earnings will be released the same day after the market closes.

Myriad Genetics Shares Fall Despite Partnership With jscreen
zacks.com18 October 2024 Sentiment: POSITIVE

MYGN partners with jscreen to expand access to high-quality hereditary cancer and reproductive genetics testing for high-risk populations.

MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests
zacks.com11 October 2024 Sentiment: POSITIVE

Myriad Genetics and Ultima Genomics to explore the latter's sequencing platform for advanced clinical tests in oncology and reproductive genomics.

Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
globenewswire.com08 October 2024 Sentiment: POSITIVE

SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations to study the use of molecular residual disease (MRD) testing in breast cancer using Myriad's Precise® MRD test.

Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
globenewswire.com03 October 2024 Sentiment: POSITIVE

SALT LAKE CITY and FREMONT, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput next-generation sequencing (NGS) platform, today announced a joint effort to explore Ultima's UG 100™ sequencing platform and its ppmSeq™ technology to advance Myriad's ability to offer groundbreaking clinical tests. Myriad has purchased a new UG 100 that will soon join other leading sequencing platforms in its new Lab of the Future facility in South San Francisco.

Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
globenewswire.com01 October 2024 Sentiment: POSITIVE

SALT LAKE CITY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a third patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market.

Should You Continue to Retain MYGN Stock in Your Portfolio?
zacks.com17 September 2024 Sentiment: POSITIVE

Myriad Genetics is advancing with strategic priorities, and bringing new products and upgrades to the market, positively influencing investors' sentiment.

What type of business is Myriad Genetics?

Myriad Genetics, Inc. is one of the largest specialized molecular diagnostic laboratories in the world. Founded in 1992, the headquarters is located in Salt Lake City, Utah. The company uses a range of patented technologies, including DNA, RNA, and protein analysis, to help understand the genetic basis of human diseases and the role that genes and their associated proteins may play in the onset and progression of disease. The company uses this information to guide the development of new molecular diagnostic and companion diagnostic tests designed to assess individual risk of developing disease in old age, determine the likelihood of a patient's response to drug therapy and dosage for the patient, or assess the risk of disease progression and recurrence.

What sector is Myriad Genetics in?

Myriad Genetics is in the Healthcare sector

What industry is Myriad Genetics in?

Myriad Genetics is in the Diagnostics & Research industry

What country is Myriad Genetics from?

Myriad Genetics is headquartered in United States

When did Myriad Genetics go public?

Myriad Genetics initial public offering (IPO) was on 06 October 1995

What is Myriad Genetics website?

https://www.myriad.com

Is Myriad Genetics in the S&P 500?

No, Myriad Genetics is not included in the S&P 500 index

Is Myriad Genetics in the NASDAQ 100?

No, Myriad Genetics is not included in the NASDAQ 100 index

Is Myriad Genetics in the Dow Jones?

No, Myriad Genetics is not included in the Dow Jones index

When was Myriad Genetics the previous earnings report?

No data

When does Myriad Genetics earnings report?

The next expected earnings date for Myriad Genetics is 07 November 2024